Prakash S Masand1, Miquel Roca, Martin S Turner, John M Kane. 1. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C. ; Psychiatric Unit, Juan March Hospital, Institut Universitari d'Investigació en Ciències de la Salut, University of Balearic Islands, Palma de Mallorca, Spain ; The Larkfield Centre, Glasgow, United Kingdom ; and the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, N.Y.
Abstract
OBJECTIVE: Although many clinicians acknowledge the occurrence of adherence problems with medication regimens among patients with schizophrenia, the problem shows no sign of improving. This may be because, in thinking about the issue, clinicians have tended to focus on patients who openly refuse or repeatedly discontinue treatment. While this description applies to only a minority of patients, in our experience, full adherence is rare; most patients are only partially adherent at best. This article examines the issue of adherence behavior in schizophrenia, focusing on the impact of partial adherence on treatment outcomes, particularly early in the course of illness. We also review potential strategies for managing the problem. DATA SOURCES: Original research and review articles published in English from 1980 to 2008 were identified using the PubMed database, with the search terms schizophrenia or psychosis combined with compliance, noncompliance, partial compliance, adherence, nonadherence, or partial adherence. STUDY SELECTION: Articles were selected by the authors on the basis of the hypotheses and/or data described. DATA SYNTHESIS: Failure to adhere to medication as prescribed can have a major impact on the course of illness and treatment outcomes in patients with schizophrenia. Even relatively short gaps in medication coverage increase the risk of relapse. Problems with adherence are common early in the course of illness, when the consequences of relapse can be particularly devastating. CONCLUSION: Clinicians in primary care and psychiatric settings need to be vigilant for signs of adherence problems among their patients and to act when necessary to prevent or alleviate the consequences of inadequate medication cover. Relapse prevention strategies, particularly for patients with early psychosis, should include ensuring that medication lapses are minimized or eliminated.
OBJECTIVE: Although many clinicians acknowledge the occurrence of adherence problems with medication regimens among patients with schizophrenia, the problem shows no sign of improving. This may be because, in thinking about the issue, clinicians have tended to focus on patients who openly refuse or repeatedly discontinue treatment. While this description applies to only a minority of patients, in our experience, full adherence is rare; most patients are only partially adherent at best. This article examines the issue of adherence behavior in schizophrenia, focusing on the impact of partial adherence on treatment outcomes, particularly early in the course of illness. We also review potential strategies for managing the problem. DATA SOURCES: Original research and review articles published in English from 1980 to 2008 were identified using the PubMed database, with the search terms schizophrenia or psychosis combined with compliance, noncompliance, partial compliance, adherence, nonadherence, or partial adherence. STUDY SELECTION: Articles were selected by the authors on the basis of the hypotheses and/or data described. DATA SYNTHESIS: Failure to adhere to medication as prescribed can have a major impact on the course of illness and treatment outcomes in patients with schizophrenia. Even relatively short gaps in medication coverage increase the risk of relapse. Problems with adherence are common early in the course of illness, when the consequences of relapse can be particularly devastating. CONCLUSION: Clinicians in primary care and psychiatric settings need to be vigilant for signs of adherence problems among their patients and to act when necessary to prevent or alleviate the consequences of inadequate medication cover. Relapse prevention strategies, particularly for patients with early psychosis, should include ensuring that medication lapses are minimized or eliminated.
Authors: Maria S Campos; Elena Garcia-Jalon; James K Gilleen; Anthony S David; Victor M D Peralta; Manuel J Cuesta Journal: Schizophr Bull Date: 2010-10-25 Impact factor: 9.306
Authors: Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder Journal: Psychopharmacology (Berl) Date: 2011-07-13 Impact factor: 4.530
Authors: Lik Hang N Lee; Charles Choi; Pavel Gershkovich; Alasdair M Barr; William G Honer; Ric M Procyshyn Journal: Eur J Drug Metab Pharmacokinet Date: 2016-12 Impact factor: 2.441
Authors: Mats O Magnusson; Mahesh N Samtani; Elodie L Plan; E Niclas Jonsson; Stefaan Rossenu; An Vermeulen; Alberto Russu Journal: Clin Pharmacokinet Date: 2017-04 Impact factor: 6.447
Authors: José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-10-28 Impact factor: 5.270
Authors: Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca Journal: Clin Drug Investig Date: 2013-02 Impact factor: 2.859